EP3330370

NOVARTIS AG
Application Number
EP17199357A
Filing Date
Apr 25, 2011
Status
Granted And Under Opposition
Jan 22, 2021
Grant Date
Feb 24, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3330370B1 was granted on Feb 24, 2021 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 6 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANT LLPNov 24, 2021ADMISSIBLE
MAIWALD GMBHNov 24, 2021ADMISSIBLE
POHLMAN, SANDRA M.Nov 24, 2021ADMISSIBLE
DEHNS LTDNov 23, 2021ADMISSIBLE
WEINZIERL, GERHARDNov 23, 2021ADMISSIBLE
STRAWMAN LIMITEDNov 22, 2021ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.